The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
Open accessAbstract
The sodium–glucose cotransporter 2 inhibitor empagliflozin reduces the risk of cardiovascular death or heart failure hospitalization in patients with chronic heart failure, but whether empagliflozin also improves clinical outcomes when initiated in patients who are hospitalized for acute heart failure is unknown. In this double-blind trial (EMPULSE; NCT04157751 ), 530 patients with a primary diagnosis of acute de novo or decompensated chronic heart failure regardless of left ventricular ejection fraction were randomly assigned to receive empagliflozin 10 mg once daily or placebo. Patients were randomized in-hospital when clinically stable (median time from hospital admission to randomization, 3 days) and were treated for up to 90 days. The primary outcome of the trial was clinical benefit, defined as a hierarchical composite of death from any cause, number of heart failure events and time to first heart failure event, or a 5 point or greater difference in change from baseline in the Kansas City Cardiomyopathy Questionnaire Total Symptom Score at 90 days, as assessed using a win ratio. More patients treated with empagliflozin had clinical benefit compared with placebo (stratified win ratio, 1.36; 95% confidence interval, 1.09–1.68; P = 0.0054), meeting the primary endpoint. Clinical benefit was observed for both acute de novo and decompensated chronic heart failure and was observed regardless of ejection fraction or the presence or absence of diabetes. Empagliflozin was well tolerated; serious adverse events were reported in 32.3% and 43.6% of the empagliflozin- and placebo-treated patients, respectively. These findings indicate that initiation of empagliflozin in patients hospitalized for acute heart failure is well tolerated and results in significant clinical benefit in the 90 days after starting treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to the hospitalization and mortality benefit in people with heart failure, SGLT2 inhibitors improve clinical stability and functional status in individuals with heart failure (301,(304)(305)(306).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [305]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to the hospitalization and mortality benefit in people with heart failure, SGLT2 inhibitors improve clinical stability and functional status in individuals with heart failure (289,292–294).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [293]
Experimental — accuracy not yet measuredIn the citing paper
“In people hospitalized for acute de novo or decompensated chronic heart failure, initiation of empagli fl ozin treatment during hospitalization reduced the primary outcome of a composite of death from any cause, number of heart failure events and time to fi rst heart failure event, or a 5-point or greater difference in change from baseline in the Kansas City Cardiomyopathy Questionnaire Total Sym”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [230]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Roth, G. A., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32203-7 · Cited by 8,600
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationHeart Disease and Stroke Statistics—2016 Update: A Report From the American Heart Association
Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., Das, S. R., de Ferranti, S., Després, J.-P., Fullerton, H. J., et al. (2016) · Circulation · doi:10.1161/cir.0000000000000350 · Cited by 6,596
Tarver, T. (2014) · Journal of Consumer Health On the Internet · doi:10.1080/15398285.2014.902284 · Cited by 5,605
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Self-citationKonstam, M. A. (2007) · JAMA · doi:10.1001/jama.297.12.1319 · Cited by 1,628
Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31824-9 · Cited by 1,408
Self-citationAngiotensin-neprilysin inhibition in acute decompensated heart failure
Velazquez, E. J., Morrow, D. A., DeVore, A. D., Duffy, C. I., Ambrosy, A. P., McCague, K., Rocha, R., & Braunwald, E. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812851 · Cited by 1,260
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad195 · Cited by 2,612
Self-citation2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citationMebazaa, A., Davison, B., Chioncel, O., Cohen-Solal, A., Diaz, R., Filippatos, G., Metra, M., Ponikowski, P., Sliwa, K., Voors, A. A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02076-1 · Cited by 1,123
Self-citationKittleson, M. M., Panjrath, G. S., Amancherla, K., Davis, L. L., Deswal, A., Dixon, D. L., Januzzi, J. L., & Yancy, C. W. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.03.393 · Cited by 554
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
Self-citation
Metadata
- Authors
- Voors, A. A., Angermann, C. E., Teerlink, J. R., Collins, S. P., Kosiborod, M., Biegus, J., Ferreira, J. P., Nassif, M. E., Psotka, M. A., Tromp, J., Borleffs, C. J. W., Ma, C., Comin-Colet, J., Fu, M., Janssens, S. P., Kiss, R. G., Mentz, R. J., Sakata, Y., Schirmer, H., Schou, M., Schulze, P. C., Spinarova, L., Volterrani, M., Wranicz, J. K., Zeymer, U., Zieroth, S., Brueckmann, M., Blatchford, J. P., Salsali, A., & Ponikowski, P.
- Affiliations
- University Medical Center Groningen (NL)
- Universitätsklinikum Würzburg (DE)
- San Francisco VA Medical Center (US)
- VA Tennessee Valley Healthcare System (US)
- The University of Sydney (AU)
- University of Wrocław (PL)
- Inserm (FR)
- Saint Luke's Hospital (US)
- Inova Health System (US)
- National University of Singapore (SG)
- Haga Hospital (NL)
- Capital Medical University (CN)
- Bellvitge University Hospital (ES)
- Sahlgrenska University Hospital (SE)
- Universitair Ziekenhuis Leuven (BE)
- Duke Medical Center (US)
- The University of Osaka (JP)
- Akershus University Hospital (NO)
- Gentofte Hospital (DK)
- Jena University Hospital (DE)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Medical University of Lodz (PL)
- Klinikum Ludwigshafen (DE)
- University of Manitoba (CA)
- Boehringer Ingelheim (Germany) (DE)
- Rutgers, The State University of New Jersey (US)
- Corresponding author
- Voors, Adriaan A.
- ORCID
- Voors, Adriaan A.
- Angermann, Christiane E.
- Teerlink, John R.
- Collins, Sean P.
- Kosiborod, Mikhail
- Biegus, Jan
- Ferreira, João Pedro
- Nassif, Michael E.
- Psotka, Mitchell A.
- Tromp, Jasper
- Ma, Changsheng
- Fu, Michael
- Janssens, Stefan P.
- Mentz, Robert J.
- Sakata, Yasushi
- Schirmer, Henrik
- Schou, Morten
- Schulze, P. Christian
- Volterrani, Maurizio
- Wranicz, Jerzy K.
- Zeymer, Uwe
- Zieroth, Shelley
- Brueckmann, Martina
- Blatchford, Jonathan P.
- Salsali, Afshin
- Ponikowski, Piotr
- Venue
- Nature Medicine
- Published
- 2022-02-28
- Volume
- 28
- Issue
- 3
- Pages
- 568-574
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC8938265
- OpenAlex
- W4214940159
- Cited by
- 951
- References
- 22
- Citations by year
- 2026: 173 · 2025: 172 · 2024: 239 · 2023: 245 · 2022: 119
- FWCI
- 135.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- HAL (submittedVersion, cc-by)
- Lirias (KU Leuven) (submittedVersion, cc-by)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- Boehringer Ingelheim and Eli Lilly and Company.
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Mechanical Circulatory Support Devices
- Keywords
- empagliflozin, SGLT2 inhibitors, acute heart failure, decompensated chronic heart failure, heart failure hospitalization, cardiovascular mortality, Kansas City Cardiomyopathy Questionnaire, symptom burden, win ratio, left ventricular ejection fraction, diabetes mellitus, drug tolerability
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Double-Blind Method, Glucosides, Heart Failure, Hospitalization, Humans, Stroke Volume, Ventricular Function, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. https://app.cochat.ai/papers/10.1038/s41591-021-01659-1
- The paper
- Voors, A. A., Angermann, C. E., Teerlink, J. R., Collins, S. P., Kosiborod, M., Biegus, J., Ferreira, J. P., Nassif, M. E., Psotka, M. A., Tromp, J., Borleffs, C. J. W., Ma, C., Comin-Colet, J., Fu, M., Janssens, S. P., Kiss, R. G., Mentz, R. J., Sakata, Y., Schirmer, H., . . . Ponikowski, P. (2022). The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nature Medicine. https://doi.org/10.1038/s41591-021-01659-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.